FDA Clears GE HealthCare's MIM LesionID Pro
- Posted on February 3, 2026
- By Google News
- 2 Views
FDA Clears GE HealthCare's MIM LesionID Pro
Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM LesionID Pro,1 an innovative solution from its MIM software portfolio that transforms whole-body tumor burden analysis for PSMA PET/CT and SPECT/CT studies into a significantly simplified process.
